Olorofim for early Valley fever meningitis
Part of Brain & nervous system, Infections clinical trials.
This trial tests a new drug called olorofim for people recently diagnosed with coccidioidomycosis (Valley fever) meningitis, a serious fungal infection of the brain lining. It aims to see if the drug is safe and effective as an early treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh at least 40 kg (about 88 lbs).
- You have been diagnosed with coccidioidomycosis meningitis (a fungal brain infection) within the last 8 weeks.
- You have symptoms from the infection that make treatment with this study drug reasonable.
- If you are a woman who could become pregnant, you must not be pregnant or breastfeeding and must use a highly effective birth control method during the study and for 30 days after.
- If you are a man with a partner who could become pregnant, you must use a highly effective birth control method during the study and for 30 days after, and not donate sperm.
- You cannot have a brain shunt or other device in your central nervous system, significant liver disease, or a known heart rhythm problem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antifungal treatment for people with certain fungal infections (Valley fever, blastomycosis, histoplasmosis) who have not done well on or can't take their current medicine. The goal is to find a better way to control the infection when the first treatment fails or causes problems.
This study tests a new antifungal medicine called olorofim, combined with standard care, for people with Valley fever that has spread beyond the lungs and hasn't improved with usual treatments. The goal is to see if it helps control the infection better than standard care alone.
This study looks at why “Valley fever” is difficult to treat or has spread beyond the lungs, and how a person’s genetics may be involved. You may be asked for blood or other samples for genetic testing and for storing samples for future research.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This study tests occidiofungin, a new antifungal medication inserted into the vagina twice a week to prevent recurring yeast infections (vulvovaginal candidiasis). The goal is to see if this treatment can stop yeast infections from coming back.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
Hear when a new Coccidioidal Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.